SPRC (SciSparc) Cash-to-Debt : 40.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is SciSparc Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SciSparc's cash to debt ratio for the quarter that ended in Jun. 2024 was 40.00.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SciSparc could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for SciSparc's Cash-to-Debt or its related term are showing as below:

SPRC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31 Med: 210.02 Max: No Debt
Current: 40

During the past 12 years, SciSparc's highest Cash to Debt Ratio was No Debt. The lowest was 0.31. And the median was 210.02.

SPRC's Cash-to-Debt is ranked better than
69.47% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs SPRC: 40.00

SciSparc Cash-to-Debt Historical Data

The historical data trend for SciSparc's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

SciSparc Cash-to-Debt Chart

SciSparc Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.74

4.19

109.13

132.37

66.79

SciSparc Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															287.67	132.37	No Debt	66.79	40.00

Competitive Comparison of SciSparc's Cash-to-Debt

For the Biotechnology subindustry, SciSparc's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciSparc's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SciSparc's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where SciSparc's Cash-to-Debt falls into.

SciSparc Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

SciSparc's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.076	/	(0.052	+	0.024)
	=	66.79

SciSparc's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.56	/	(0.038	+	0.026)
	=	40.00

SciSparc (NAS:SPRC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

SciSparc Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of SciSparc's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SciSparc Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (NAS:SPRC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916

Website

https://www.scisparc.com

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.